Last reviewed · How we verify
Fluorometholone 1% topical ocular steroid
At a glance
| Generic name | Fluorometholone 1% topical ocular steroid |
|---|---|
| Also known as | FML |
| Sponsor | United States Naval Medical Center, San Diego |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Comparison of the Postoperative Use of Dextenza vs a Standard Regimen After PRK (PHASE4)
- The Use of MMC During PRK and Its Effect on Postoperative Topical Steroid Requirements (PHASE2, PHASE3)
- Treatment of Corneal Infiltrates Secondary to Epidemic Keratoconjunctivitis (PHASE4)
- Ocular Micro-vascular Research Base on Functional Slip Lamp Biomicroscopy (PHASE4)
- Ocular-hypertensive Response to Topical Steroids in Children After Bilateral Strabismus Surgery (PHASE4)
- Topical Steroid Treatment For Dry Eye (NA)
- Topical Cyclosporine vs. Placebo for Epiphora Associated With Docetaxel (PHASE2)
- Randomized Controlled Trial of Subconjunctival Bevacizumab Injection in Impending Recurrent Pterygium (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: